Business
Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer
Eloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer.
About this update from Eloxx Pharmaceuticals, Inc.
[{"type":"text","content":"\n\n\n\nEloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nEloxx Pharmaceuticals Appoints Gregory Weaver as Chief Financial Officer\nPR Newswire\nSAN DIEGO, TEL AVIV, Israel and BOSTON, Sept. 26, 2017\n\n\n\nSAN DIEGO, TEL AVIV, Israel and BOSTON, Sept. 26, 2017 /PRNewswire/ -- Sevion Therapeutics, Inc. (OTCQB:SVON) and Eloxx Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company developing novel small molecule medicines for genetic diseases caused by nonsense mutations, today announced the appointment of Gregory Weaver, M.B.A., as Chief Financial Officer. Mr. Weaver is a seasoned financial executive with more than 30 years of experience in leading business and financial operations for private and public companies, including financing transactions, strategic planning, investor relations, and business development initiatives.\n\n\"Greg brings a wealth of biopharmaceutical sector experience, both as a CFO and Board Member, as well as the financial and business acumen ideally suited to Eloxx,\" said Dr. Silvia Noiman, CEO and co-founder of Eloxx. \"Greg's broad industry perspective, robust understanding of the crucial operational aspects of a growing company, and his demonstrated ability to manage multiple strategic functions will be essential as we focus our efforts on building a leading organization that creates value and improves the lives of patients suffering from devastating genetic diseases.\"\n\nDuring his career, Mr. Weaver has been instrumental in raising more than $900 million in private and public equity and debt financing for both U.S. and international life science companies. Prior to joining Eloxx, Mr. Weaver served as Chief Financial Officer of Prometic Life Sciences, where he led the Company's global financial team. Previously, Mr. Weaver served as Executive Vice President and Chief Financial Officer of Oryzon Genomics where he managed the Company's IPO financing. Earlier in his career, Mr. Weaver served as Chief Financial Officer of several other life sciences companies, i...